Skip to main navigation
Skip to main content
KASL
Contact us
mobile search button
mobile menu button
Search
Advanced Search
ABOUT
HOME
ABOUT
Aims and scope
About the journal
Editorial board
Open access
Subscription information
Editorial board meeting
Contact us
BROWSE ARTICLES
All issues
Ahead-of-print
Current issue
Article category
Topics
Snapshot
Most viewed articles
Most downloaded articles
Most cited articles
Search
Video abstract
Metrics
FOR CONTRIBUTORS
Publish with
CMH
Instructions for authors
Peer review and publishing
CMH Guidelines for reviewers
Checklist
E-submission
Copyright transfer agreement
ABOUT
Aims and scope
About the journal
Editorial board
Open access
Subscription information
Editorial board meeting
Contact us
BROWSE ARTICLES
All issues
Ahead-of-print
Current issue
Article category
Topics
Snapshot
Most viewed articles
Most downloaded articles
Most cited articles
Search
Video abstract
Metrics
FOR CONTRIBUTORS
Publish with
CMH
Instructions for authors
Peer review and publishing
CMH Guidelines for reviewers
Checklist
E-submission
Copyright transfer agreement
Page Path
HOME
Search
Dima Mazen Qato
WHERE t1.sid in(parameter_dbtbl_author like '%Dima Mazen Qato%') and t1.xml_status <> 99
1
results for
"Dima Mazen Qato"
Filter
Article category
Research Letter (1)
Keywords
Fatty liver (1)
GLP-1 (1)
MASH (1)
Semaglutide (1)
SLD (1)
Publication year
2026 (1)
Keywords
Fatty liver (1)
GLP-1 (1)
MASH (1)
Semaglutide (1)
SLD (1)
Cancel
Close
Publication Year
2026 (1)
Cancel
Close
Funded articles
Cancel
Close
"Dima Mazen Qato"
Research Letter
National trends in resmetirom prescriptions for metabolic dysfunction-associated steatohepatitis in the USA
Brian P. Lee, Christopher Scannell, Matt Dukewich, Jennifer L. Dodge, Norah A. Terrault, Dima Mazen Qato
Clin Mol Hepatol
2026;32(2):e185-e188.
Published online February 5, 2026
DOI:
https://doi.org/10.3350/cmh.2025.1414
PDF
1,823
View
86
Download
First
Prev
Page
of 1
Next
Last
×
TOP
First
Prev
